18 February 2014 - Germany is considering legislation this week that would force drugmakers to report the reduced prices they negotiate with insurers, potentially pressuring prices lower elsewhere in Europe. Pharmaceutical companies would have to report rebated prices, instead of their original list prices, to databases such as IMS Health, said Ina Klaus, a Health Ministry spokeswoman in Berlin. The revised law will make it clear that the list price isn’t what’s paid in Germany, she said. German prices are influential because other countries use them as a reference. While incremental, the change would add to the pressure on drugmakers, which have faced a series of moves by European companies to keep medicine prices down in the wake of the economic crisis.

For more details, go to: http://www.bloomberg.com/news/2014-02-17/german-proposal-to-report-drug-prices-has-roche-concerned.html